Metastatic cancer

Common Name(s)

Metastatic cancer

Description for this condition is not yet available.
 

Advocacy and Support Organizations

 

Condition Specific Organizations

Following organizations serve the condition "Metastatic cancer" for support, advocacy or research.

There are currently no organizations listed in Disease InfoSearch that support this condition. Create a listing.

 

 

General Support Organizations

Not finding the support you need? Show General Support Organizations

 
 
Top

How do you compare to others with this condition?

Privately answer questions about your health. Let resources, you select, come to you.

Anonymously share and see how your answers compare with others with this condition while privately providing key pieces of information to medical researchers, disease advocacy groups, and others ONLY YOU select to help speed up cures and better alternatives.

 
 

Advocacy and Support Organizations

 

Condition Specific Organizations

Following organizations serve the condition "Metastatic cancer" for support, advocacy or research.

There are currently no organizations listed in Disease InfoSearch that support this condition. Create a listing.

 

 

General Support Organizations

Not finding the support you need? Show General Support Organizations

 
 
 
 
Top

Scientific Literature

Articles from the PubMed Database

Research articles describe the outcome of a single study. They are the published results of original research.
The terms "Metastatic cancer" returned 4687 free, full-text research articles on human participants. First 3 results:

A phase II clinical study of combining FOLFIRI and bevacizumab plus erlotinib in 2nd-line chemotherapy for patients with metastatic colorectal cancer.
 

Author(s): Zhifei Zhao, Jianxiong Li, Rui Ye, Xuan Wu, Lingling Gao, Baolong Niu

Journal: Medicine (Baltimore). 2017 Jul;96(30):e7182.

 

We conducted an open-label single-arm phase II study by combining irinotecan (FOLFIRI) and bevacizumab (BV) plus erlotinib (ER) in 2nd-line chemotherapy for patients with metastatic colorectal cancer (mCRC).Eligible mCRC patients received 1st-line standard chemotherapy but still had ...

Last Updated: 26 Jul 2017

Go To URL
Post hoc analyses of East Asian patients from the randomized placebo-controlled PREVAIL trial of enzalutamide in patients with chemotherapy-naïve, metastatic castration-resistant prostate cancer.
 

Author(s): Choung Soo Kim, Young Deuk Choi, Sang Eun Lee, Hyun Moo Lee, Takeshi Ueda, Junji Yonese, Takashi Fukagai, Edmund Chiong, Weber Lau, Sarang Abhyankar, Ad Theeuwes, Bertrand Tombal, Tomasz M Beer, Go Kimura

Journal: Medicine (Baltimore). 2017 Jul;96(27):e7223.

 

Enzalutamide is an androgen receptor (AR) inhibitor that acts on different steps in the AR signaling pathway. In PREVAIL, an international, phase III, double-blind, placebo-controlled trial, enzalutamide significantly reduced the risk of radiographic progression by 81% (hazard ratio ...

Last Updated: 6 Jul 2017

Go To URL
A randomized phase II study of gemcitabine plus Z-360, a CCK2 receptor-selective antagonist, in patients with metastatic pancreatic cancer as compared with gemcitabine plus placebo.
 

Author(s): Makoto Ueno, Chung Pin Li, Masafumi Ikeda, Hiroshi Ishii, Nobumasa Mizuno, Taketo Yamaguchi, Tatsuya Ioka, Do Youn Oh, Wataru Ichikawa, Takuji Okusaka, Yutaka Matsuyama, Daichi Arai, Li Tzong Chen, Young Suk Park, Junji Furuse

Journal: Cancer Chemother. Pharmacol.. 2017 Aug;80(2):307-315.

 

We investigated the efficacy and safety of 60, 120, or 240 mg of Z-360, which is a highly potent cholecystokinin2-receptor-selective antagonist, combined with gemcitabine in patients with metastatic pancreatic cancer.

Last Updated: 21 Jun 2017

Go To URL

Reviews from the PubMed Database

Review articles summarize what is currently known about a disease. They discuss research previously published by others.
The terms "Metastatic cancer" returned 511 free, full-text review articles on human participants. First 3 results:

Recent Advances in Targeting the EGFR Signaling Pathway for the Treatment of Metastatic Colorectal Cancer.
 

Author(s): Yuji Miyamoto, Koichi Suyama, Hideo Baba

Journal:

 

Outcomes for metastatic colorectal cancer (mCRC) patients have been improved by treatment with anti-epidermal growth factor receptor (anti-EGFR) antibodies, particularly when combined with predictive biomarkers to select patients lacking RAS mutations. New technologies such as liquid ...

Last Updated: 3 Apr 2017

Go To URL
Overall survival of patients with KRAS wild-type tumor treated with FOLFOX/FORFIRI±cetuximab as the first-line treatment for metastatic colorectal cancer: A meta-analysis.
 

Author(s): Ya-Fan Yang, Gui-Ying Wang, Jing-Li He, Feng-Peng Wu, Yan-Ni Zhang

Journal: Medicine (Baltimore). 2017 Mar;96(12):e6335.

 

The addition of cetuximab to FOLFIRI or FOLFOX as the first-line treatment for metastatic colorectal cancer (mCRC) was shown to reduce the risk of disease progression and increase the chance of response in patients with KRAS wild-type disease. An updated systematic meta-analysis was ...

Last Updated: 22 Mar 2017

Go To URL
The effect of anti-angiogenic agents on overall survival in metastatic oesophago-gastric cancer: A systematic review and meta-analysis.
 

Author(s): David L Chan, Katrin M Sjoquist, David Goldstein, Timothy J Price, Andrew J Martin, Yung-Jue Bang, Yoon-Koo Kang, Nick Pavlakis

Journal:

 

Studies of anti-angiogenic agents (AAs), combined with chemotherapy (chemo) or as monotherapy in metastatic oesophago-gastric cancer (mOGC), have reported mixed outcomes. We undertook systematic review and meta-analysis to determine their overall benefits and harms.

Last Updated: 21 Feb 2017

Go To URL
 
 
Top

Clinical Trial Information This information is provided by ClinicalTrials.gov

Last Updated: 2 Jan 2017

Go to URL
Clinical Sequencing Project for Metastatic Cancer Patients for Personalized Cancer Clinic.
 

Status: Recruiting

Condition Summary: Metastatic Cancer

 

Last Updated: 15 Feb 2017

Go to URL

Last Updated: 7 Jul 2017

Go to URL